

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 8, 2022**

**GLOBUS MEDICAL, INC.**

(Exact name of registrant as specified in charter)

**DELAWARE**  
(State or other jurisdiction  
of incorporation)

**001-35621**  
(Commission  
File Number)

**04-3744954**  
(IRS Employer  
Identification No.)

**2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403-5214**  
(Address of principal executive offices) (Zip Code)

**(610) 930-1800**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbols	Name of exchange on which registered
Class A Common Stock, par value \$.001 per share	GMED	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 2.02. Results of Operations and Financial Condition.**

On November 8, 2022, we issued a press release reporting, among other things, our sales and operating results for the three-month period ended September 30, 2022. A copy of the press release is furnished as Exhibit 99.1 to this report.

In accordance with general instruction B.2 to Form 8-K, the information included in this Item 2.02, and the exhibits attached hereto, shall be deemed to be “furnished” and shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

**Item 9.01. Financial Statements and Exhibits.**

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#">Press Release dated November 8, 2022</a>
104	The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GLOBUS MEDICAL, INC.**  
(Registrant)

Dated: November 8, 2022

**/s/ KEITH PFEIL**

Keith Pfeil  
Chief Financial Officer  
Chief Accounting Officer  
Senior Vice President  
(Principal Financial Officer)

**Globus Medical Reports Third Quarter 2022 Results**

AUDUBON, PA, November 8, 2022: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2022.

- Worldwide net sales were \$254.1 million, an increase of 10.6%, or 12.6% on a constant currency basis
- GAAP net income for the quarter was \$47.4 million
- GAAP diluted earnings per share (“EPS”) was \$0.47 and non-GAAP diluted EPS was \$0.50
- Non-GAAP adjusted EBITDA was \$82.8 million, or 32.6% of net sales

“Our third quarter sales grew 12.6% on a constant currency basis, as we continue to make market share gains by providing industry leading innovative solutions in spine care,” commented Dan Scavilla, President and CEO. “Our U.S. Spine business grew an impressive 9.0%, which is evidence of our ability to hold the share gains we’ve made in the past several years, while also continuing to take new share across the U.S. market. International Spine sales increased by 11.1% on an as-reported basis, and 24.8% on a constant currency basis as we continue to increase our brand recognition on the global healthcare stage. Enabling Technologies grew 19.0% to \$24.1 million, driven by continued robotic system demand and new interest in our Excelsius3D™ imaging system. Globus Medical remains well positioned to continue providing innovative procedural solutions to help patients with musculoskeletal disorders.”

Worldwide net sales for the third quarter of 2022 were \$254.1 million, an as-reported increase of 10.6% over the third quarter of 2021, and an increase of 12.6% on a constant currency basis. U.S. net sales for the third quarter of 2022 increased by 9.5% compared to the third quarter of 2021. International net sales increased by 17.7% over the third quarter of 2021 on an as-reported basis, and an increase of 31.8% on a constant currency basis.

GAAP net income for the third quarter of 2022 was \$47.4 million, an increase of 0.5% over the same period in the prior year. Diluted EPS for the third quarter was \$0.47, compared to \$0.45 for the third quarter of 2021. Non-GAAP diluted EPS for the third quarter of 2022 was in line with the same period in the prior year at \$0.50, and includes current period non-operating headwinds related to a higher effective tax rate and unfavorable currency fluctuations.

Net cash provided by operating activities was \$32.9 million, and non-GAAP free cash flow was \$20.9 million for the third quarter of 2022. The Company remains debt free.

**2022 Annual Guidance**

The Company today reaffirmed its full year 2022 guidance of \$1.025 billion in net sales and decreased full year 2022 guidance for non-GAAP diluted earnings per share to \$2.03 from \$2.10 to account for the impact of unfavorable currency fluctuations and a higher effective tax rate.

---

**Conference Call Information**

Globus Medical will hold a teleconference to discuss its third quarter 2022 results with the investment community at 4:30 p.m. Eastern Time today. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at <https://www.investors.globusmedical.com/news-events/events-webcasts>.

To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The audio archive will be available after the call on the Investor page of the Globus Medical website.

**About Globus Medical, Inc.**

Based in Audubon, Pennsylvania, Globus Medical, Inc. was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at [www.globusmedical.com](http://www.globusmedical.com).

---

## Non-GAAP Financial Measures

To supplement our financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), management uses certain non-GAAP financial measures. For example, non-GAAP Adjusted EBITDA, which represents net income before interest income, net and other non-operating expenses, provision for income taxes, depreciation and amortization, stock-based compensation expense, provision for litigation, acquisition related costs/licensing, and acquisition of in-process research and development, is useful as an additional measure of operating performance, and particularly as a measure of comparative operating performance from period to period, as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance, and it removes the effect of our capital structure, asset base, income taxes and interest income and expense. Our management also uses non-GAAP Adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections. Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized. Acquisition related costs/licensing represents the change in fair value of business-acquisition-related contingent consideration; costs related to integrating recently acquired businesses, including but not limited to costs to exit or convert contractual obligations, severance, and information system conversion; and specific costs related to the consummation of the acquisition process such as banker fees, legal fees, and other acquisition related professional fees, as well as one-time licensing fees. Acquisition of in-process research and development represents the expensing of acquired assets with no alternative future use and related fees.

In addition, for the period ended September 30, 2022 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP Diluted Earnings Per Share, which represent net income and diluted earnings per share excluding the provision for litigation, amortization of intangibles, acquisition related costs/licensing, acquisition of in-process research and development, and the tax effects of all of the foregoing adjustments. The tax effect adjustment represents the tax effect of the pre-tax non-GAAP adjustments excluded from non-GAAP net income. The tax impact of the non-GAAP adjustments is calculated based on the consolidated effective tax rate on a GAAP basis, applied to the non-GAAP adjustments, unless the underlying item has a materially different tax treatment, in which case the estimated tax rate applicable to the adjustment is used. We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operating performance from period to period as they remove the effects of litigation, amortization of intangibles, acquisition related costs/licensing, acquisition of in-process research and development, and the tax effects of all of the foregoing adjustments, which we believe are not reflective of underlying business trends. Additionally, for the period ended September 30, 2022 and for other comparative periods, we also define the non-GAAP measure of free cash flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment. We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions. Furthermore, the non-GAAP measure of constant currency net sales growth is calculated by translating current year net sales at the same average exchange rates in effect during the applicable prior year period. We believe constant currency net sales growth provides insight to the comparative increase or decrease in period net sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates.

Non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, free cash flow and constant currency net sales growth are not calculated in conformity with U.S. GAAP. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with U.S. GAAP. These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results. Our definitions of non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, free cash flow and constant currency net sales growth may differ from that of other companies and therefore may not be comparable.

---

## Safe Harbor Statements

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the U.S. Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the U.S. Securities and Exchange Commission. These documents are available at [www.sec.gov](http://www.sec.gov). Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

---

**GLOBUS MEDICAL, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF INCOME**  
(unaudited)

<i>(In thousands, except per share amounts)</i>	Three Months Ended September 30,		Nine Months Ended September 30,	
	2022	2021	2022	2021
<b>Net sales</b>	<b>\$ 254,148</b>	<b>\$ 229,721</b>	<b>\$ 748,345</b>	<b>\$ 708,081</b>
Cost of goods sold	<u>65,497</u>	<u>58,554</u>	<u>193,134</u>	<u>177,427</u>
<b>Gross profit</b>	<b><u>188,651</u></b>	<b><u>171,167</u></b>	<b><u>555,211</u></b>	<b><u>530,654</u></b>
<b>Operating expenses:</b>				
Research and development	18,701	15,853	53,508	46,324
Selling, general and administrative	106,576	96,444	314,042	301,589
Provision for litigation	—	605	2,341	511
Amortization of intangibles	4,324	4,573	13,229	13,970
Acquisition related costs	(652)	363	(1,832)	14,507
<b>Total operating expenses</b>	<b><u>128,949</u></b>	<b><u>117,838</u></b>	<b><u>381,288</u></b>	<b><u>376,901</u></b>
<b>Operating income/(loss)</b>	<b>59,702</b>	<b>53,329</b>	<b>173,923</b>	<b>153,753</b>
<b>Other income/(expense), net</b>				
Interest income/(expense), net	3,899	2,105	8,918	7,358
Foreign currency transaction gain/(loss)	(2,210)	(898)	(3,708)	(969)
Other income/(expense)	74	(84)	1,770	437
<b>Total other income/(expense), net</b>	<b><u>1,763</u></b>	<b><u>1,123</u></b>	<b><u>6,980</u></b>	<b><u>6,826</u></b>
<b>Income/(loss) before income taxes</b>	<b>61,465</b>	<b>54,452</b>	<b>180,903</b>	<b>160,579</b>
Income tax provision	<u>14,034</u>	<u>7,241</u>	<u>40,799</u>	<u>26,494</u>
<b>Net income/(loss)</b>	<b><u>\$ 47,431</u></b>	<b><u>\$ 47,211</u></b>	<b><u>\$ 140,104</u></b>	<b><u>\$ 134,085</u></b>
<b>Other comprehensive income/(loss), net of tax:</b>				
Unrealized gain/(loss) on marketable securities	(4,380)	(991)	(18,239)	(3,431)
Foreign currency translation gain/(loss)	(2,478)	(491)	(7,215)	(3,578)
Total other comprehensive income/(loss), net of tax	<u>(6,858)</u>	<u>(1,482)</u>	<u>(25,454)</u>	<u>(7,009)</u>
<b>Comprehensive income/(loss)</b>	<b><u>\$ 40,573</u></b>	<b><u>\$ 45,729</u></b>	<b><u>\$ 114,650</u></b>	<b><u>\$ 127,076</u></b>
<b>Earnings per share:</b>				
Basic	<u>\$ 0.48</u>	<u>\$ 0.47</u>	<u>\$ 1.39</u>	<u>\$ 1.33</u>
Diluted	<u>\$ 0.47</u>	<u>\$ 0.45</u>	<u>\$ 1.36</u>	<u>\$ 1.30</u>
<b>Weighted average shares outstanding:</b>				
Basic	<u>99,652</u>	<u>101,104</u>	<u>100,638</u>	<u>100,477</u>
Diluted	<u>101,417</u>	<u>104,418</u>	<u>102,789</u>	<u>103,430</u>



**GLOBUS MEDICAL, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(unaudited)

<i>(In thousands, except share and per share values)</i>	September 30, 2022	December 31, 2021
<b>ASSETS</b>		
<b>Current assets:</b>		
Cash and cash equivalents	\$ 134,223	\$ 193,069
Short-term marketable securities	271,063	250,378
Accounts receivable, net of allowances of \$4,284 and \$4,962, respectively	206,307	164,436
Inventories	282,408	237,001
Prepaid expenses and other current assets	23,803	18,417
Income taxes receivable	2,197	1,215
<b>Total current assets</b>	<b>920,001</b>	<b>864,516</b>
Property and equipment, net of accumulated depreciation of \$332,917 and \$305,575, respectively	236,342	221,076
Long-term marketable securities	503,965	562,475
Intangible assets, net	54,057	68,660
Goodwill	181,774	179,708
Other assets	35,654	36,334
Deferred income taxes	44,719	24,494
<b>Total assets</b>	<b>\$ 1,976,512</b>	<b>\$ 1,957,263</b>
<b>LIABILITIES AND EQUITY</b>		
<b>Current liabilities:</b>		
Accounts payable	\$ 31,971	\$ 21,955
Accrued expenses	88,361	91,168
Income taxes payable	1,308	1,046
Business acquisition liabilities	11,329	11,770
Deferred revenue	12,286	12,025
Payable to broker	—	2,200
<b>Total current liabilities</b>	<b>145,255</b>	<b>140,164</b>
Business acquisition liabilities, net of current portion	52,965	58,755
Deferred income taxes	1,578	4,314
Other liabilities	12,603	12,642
<b>Total liabilities</b>	<b>212,401</b>	<b>215,875</b>
<b>Equity:</b>		
Class A common stock; \$0.001 par value. Authorized 500,000,000 shares; issued and outstanding 77,401,459 and 79,113,916 shares at September 30, 2022 and December 31, 2021, respectively	77	79
Class B common stock; \$0.001 par value. Authorized 275,000,000 shares; issued and outstanding 22,430,097 and 22,430,097 shares at September 30, 2022 and December 31, 2021, respectively	22	22
Additional paid-in capital	606,352	553,787
Accumulated other comprehensive income/(loss)	(32,226)	(6,772)
Retained earnings	1,189,886	1,194,272
<b>Total equity</b>	<b>1,764,111</b>	<b>1,741,388</b>
<b>Total liabilities and equity</b>	<b>\$ 1,976,512</b>	<b>\$ 1,957,263</b>

**GLOBUS MEDICAL, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**(unaudited)**

Nine Months Ended

September 30,

2022                      2021

(In thousands)

**Cash flows from operating activities:**

Net income	\$	140,104	\$	134,085
Adjustments to reconcile net income to net cash provided by operating activities:				
Depreciation and amortization		51,342		53,038
Amortization of premium (discount) on marketable securities		4,446		1,763
Write-down for excess and obsolete inventories, net		5,890		5,570
Stock-based compensation expense		24,303		22,781
Allowance for doubtful accounts		(396)		883
Change in fair value of business acquisition liabilities		(2,043)		14,336
Change in deferred income taxes		(17,014)		(3,131)
(Gain)/loss on disposal of assets, net		241		383
Payment of business acquisition related liabilities		(2,021)		—
(Increase)/decrease in:				
Accounts receivable		(46,200)		(19,928)
Inventories		(48,650)		(9,161)
Prepaid expenses and other assets		(6,866)		(794)
Increase/(decrease) in:				
Accounts payable		10,407		2,521
Accrued expenses and other liabilities		1,660		7,500
Income taxes payable/receivable		(710)		(9,825)
<b>Net cash provided by/(used in) operating activities</b>		<b>114,493</b>		<b>200,021</b>

**Cash flows from investing activities:**

Purchases of marketable securities		(322,100)		(347,057)
Maturities of marketable securities		239,126		171,886
Sales of marketable securities		89,978		82,882
Purchases of property and equipment		(55,707)		(39,853)
Acquisition of businesses, net of cash acquired and purchases of intangible and other assets		(1,175)		—
<b>Net cash provided by/(used in) investing activities</b>		<b>(49,878)</b>		<b>(132,142)</b>

**Cash flows from financing activities:**

Payment of business acquisition liabilities		(5,288)		(4,763)
Proceeds from exercise of stock options		26,228		59,933
Repurchase of common stock		(144,493)		—
<b>Net cash provided by/(used in) financing activities</b>		<b>(123,553)</b>		<b>55,170</b>
Effect of foreign exchange rates on cash		92		(570)
<b>Net increase/(decrease) in cash and cash equivalents</b>		<b>(58,846)</b>		<b>122,479</b>
Cash and cash equivalents at beginning of period		193,069		239,397
<b>Cash and cash equivalents at end of period</b>	<b>\$</b>	<b>134,223</b>	<b>\$</b>	<b>361,876</b>

Supplemental disclosures of cash flow information:

Income taxes paid	\$	58,301	\$	39,450
Purchases of property and equipment included in accounts payable and accrued expenses	\$	5,341	\$	3,491

## Supplemental Financial Information

### Net Sales by Product Category:

<i>(In thousands)</i>	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2022	2021	2022	2021
Musculoskeletal Solutions	\$ 230,060	\$ 209,478	\$ 681,704	\$ 652,157
Enabling Technologies	24,088	20,243	66,641	55,924
Total net sales	<u>\$ 254,148</u>	<u>\$ 229,721</u>	<u>\$ 748,345</u>	<u>\$ 708,081</u>

### Liquidity and Capital Resources:

<i>(In thousands)</i>	September 30,	December 31,
	2022	2021
Cash and cash equivalents	\$ 134,223	\$ 193,069
Short-term marketable securities	271,063	250,378
Long-term marketable securities	503,965	562,475
Total cash, cash equivalents and marketable securities	<u>\$ 909,251</u>	<u>\$ 1,005,922</u>

The following tables reconcile GAAP to Non-GAAP financial measures.

### Non-GAAP Adjusted EBITDA Reconciliation Table:

<i>(In thousands, except percentages)</i>	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2022	2021	2022	2021
Net income/(loss)	\$ 47,431	\$ 47,211	\$ 140,104	\$ 134,085
Interest (income)/expense, net	(3,899)	(2,105)	(8,918)	(7,358)
Provision for income taxes	14,034	7,241	40,799	26,494
Depreciation and amortization	17,578	16,751	51,342	53,038
EBITDA	<u>75,144</u>	<u>69,098</u>	<u>223,327</u>	<u>206,259</u>
Stock-based compensation expense	8,314	7,451	24,303	22,781
Provision for litigation	—	605	2,341	511
Acquisition related costs/licensing	(652)	1,181	(938)	16,688
Adjusted EBITDA	<u>\$ 82,806</u>	<u>\$ 78,335</u>	<u>\$ 249,033</u>	<u>\$ 246,239</u>
Net income/(loss) as a percentage of net sales	18.7%	20.6%	18.7%	18.9%
Adjusted EBITDA as a percentage of net sales	32.6%	34.1%	33.3%	34.8%

### Non-GAAP Net Income Reconciliation Table:

<i>(In thousands)</i>	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2022	2021	2022	2021
Net income/(loss)	\$ 47,431	\$ 47,211	\$ 140,104	\$ 134,085
Provision for litigation	—	605	2,341	511
Amortization of intangibles	4,324	4,573	13,229	13,970
Acquisition related costs/licensing	(652)	1,181	(938)	16,688
Tax effect of adjusting items	(839)	(846)	(3,280)	(4,906)
Non-GAAP net income/(loss)	<u>\$ 50,264</u>	<u>\$ 52,724</u>	<u>\$ 151,456</u>	<u>\$ 160,348</u>

**Non-GAAP Diluted Earnings Per Share Reconciliation Table:**

<i>(In thousands)</i>	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2022	2021	2022	2021
Diluted earnings per share, as reported	\$ 0.47	\$ 0.45	\$ 1.36	\$ 1.30
Provision for litigation	—	—	0.02	—
Amortization of intangibles	0.04	0.05	0.13	0.14
Acquisition related costs/licensing	(0.01)	0.01	(0.01)	0.16
Tax effect of adjusting items	(0.01)	(0.01)	(0.03)	(0.05)
Non-GAAP diluted earnings per share	<u>\$ 0.50</u>	<u>\$ 0.50</u>	<u>\$ 1.47</u>	<u>\$ 1.55</u>

\*amounts might not add due to rounding

**Non-GAAP Free Cash Flow Reconciliation Table:**

<i>(In thousands)</i>	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2022	2021	2022	2021
Net cash provided by operating activities	\$ 32,920	\$ 77,262	\$ 114,493	\$ 200,021
Purchases of property and equipment	(11,983)	(17,795)	(55,707)	(39,853)
Free cash flow	<u>\$ 20,937</u>	<u>\$ 59,467</u>	<u>\$ 58,786</u>	<u>\$ 160,168</u>

**Non-GAAP Net Sales on a Constant Currency Basis Comparative Table:**

<i>(In thousands, except percentages)</i>	Three Months Ended		Reported Net Sales Growth	Currency Impact on Current Period Net Sales	Constant Currency Net Sales Growth
	September 30,				
	2022	2021			
United States	\$ 217,024	\$ 198,172	9.5%	\$ —	9.5%
International	37,124	31,549	17.7%	(4,445)	31.8%
Total net sales	<u>\$ 254,148</u>	<u>\$ 229,721</u>	10.6%	<u>\$ (4,445)</u>	12.6%

<i>(In thousands, except percentages)</i>	Nine Months Ended		Reported Net Sales Growth	Currency Impact on Current Period Net Sales	Constant Currency Net Sales Growth
	September 30,				
	2022	2021			
United States	\$ 638,707	\$ 606,608	5.3%	\$ —	5.3%
International	109,638	101,473	8.0%	(9,283)	17.2%
Total net sales	<u>\$ 748,345</u>	<u>\$ 708,081</u>	5.7%	<u>\$ (9,283)</u>	7.0%

**Contact:**

Brian Kearns  
Senior Vice President, Business Development and Investor Relations  
Phone: (610) 930-1800  
Email: [investors@globusmedical.com](mailto:investors@globusmedical.com)  
[www.globusmedical.com](http://www.globusmedical.com)